



NormOxys Appoints Industry Leader Jean-Pierre Garnier, PhD, to Board of Directors

Former GSK CEO and SP President Joins BOD as Chairman

BOSTON, MA –November 5, 2008 – NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased cells, announced today the appointment of Jean-Pierre Garnier, PhD, as Chairman of its Board of Directors, effective immediately. Dr. Garnier is a well-known and recognized industry leader, having served as CEO of GlaxoSmithKline for seven years, following his tenure as CEO of SmithKline Beecham of a decade. He also served as President of Schering-Plough's US business division.

"We could not be more delighted that Dr. Garnier has joined the NormOxys board as Chairman," said Prof. Jean-Marie Lehn, PhD, Nobel Laureate in Chemistry and NormOxys Co-Founder. "Jean-Pierre's experience and insights will guide NormOxys' growth and his decision to join NormOxys is validation of the company's breakthrough approach with oxyrens, a new class of drugs that can treat a range of diseases in a whole new way by overcoming oxygen deficiency in cells."

Jean-Pierre Garnier assumed the CEO role at GlaxoSmithKline with the merger of SmithKline Beecham and Glaxo Wellcome, and served in that capacity from 2001 to his retirement from GSK in 2008. He joined SmithKline Beecham in 1990 and became CEO in 2000. Prior to SmithKline Beecham, Dr. Garnier served as President of Schering-Plough's US business division. Dr. Garnier currently serves as CEO of Pierre Fabre Labs, a pharmaceutical and cosmetic company located in France. He also serves on the boards of directors of the United Technologies Corporation and Renault S.A.

Dr. Garnier's accomplishments have been recognized with many prestigious appointments and awards. He was appointed to Prime Minister Gordon Brown's UK Business Advisory Council in 2007 and was also selected by President Chirac of France to receive the Chevalier de la Légion d'Honneur and subsequently was promoted by President Nicolas Sarkozy to Officier de Légion d'Honneur in 2008. Dr. Garnier received the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research from the Cancer Research Institute in 2007. He received the Humanitarian Award from the Sabin Vaccine Institute in 2002 and was named one of 50 "Stars of Europe" by BusinessWeek magazine and presented with the Marco Polo Award for GlaxoSmithKline's commitment to China in 2001. In 2009 he was made Knight Commander of the British Empire by the Queen for his activity fighting AIDS in Africa.

Dr. Garnier holds a PhD in pharmacology and an MS in pharmaceutical science from the University Louis Pasteur in France. As a Fulbright Scholar, he earned an MBA at Stanford University and in 2002 he was honored with the Fulbright Association's Lifetime Achievement Medal.

About NormOxys

NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body's ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency. This new class of drugs can be potentially developed in a broad range of clinical indications where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissues, such as cancer, cardiovascular diseases, anemia, Alzheimer's' disease, stroke and diabetic retinopathy. The company is based in Boston, MA and was founded by Prof. Claude Nicolau, PhD, and Nobel Laureate Prof. Jean-Marie Lehn, PhD, based on their groundbreaking investigations in chemistry and cellular biophysics. To learn more about NormOxys, please visit the Company's website at www.normoxys.com.